Butylphthalide, described chemically as 3-butyl-1(3H)-isobenzofuranone (CAS 6066-49-5, molecular formula C12H14O2, relative molecular mass 190.24), is supplied as a pharmaceutical-grade active pharmaceutical ingredient for oral and injectable dosage-form manufacture. The product is a pale yellow to colourless oily liquid at 20–25°C, practically insoluble in water and miscible with ethanol, medium-chain triglycerides, and propylene glycol. Because butylphthalide contains a single stereogenic centre, the synthetic API must control enantiomeric composition by chiral HPLC where the applicable monograph requires it. The product is not defined by a single international pharmacopoeial model number; instead, manufacturer batch codes identify oral and injectable release profiles. Oral grade batches are released against identity, assay, related substances, residual solvents, and heavy metals. Injectable grade batches add bacterial endotoxin, sterility, and subvisible particulate controls. The API is indicated for the treatment of ischaemic stroke-related neurological deficit through multi-target activity: improvement of cerebral microcirculation, inhibition of platelet aggregation, and protection of mitochondrial function. Published head-to-head clinical outcome data comparing butylphthalide with other neuroprotectants are limited; route-specific specification choices should therefore be driven by quality targets rather than therapeutic claims.

The synthetic route typically involves cyclisation of a substituted benzyl alcohol or similar intermediate to the isobenzofuranone core; residual-solvent profiles depend on the route and should comply with ICH Q3C. The lactone ring is stable under neutral and mild acidic conditions but may open under strongly alkaline aqueous conditions. Formulators should avoid prolonged exposure to pH above 8.0 unless forced degradation studies demonstrate acceptable impurity formation. Pharmacopoeial reference to butylphthalide is primarily through the Chinese Pharmacopoeia and manufacturer-specific specifications; no Ph. Eur. or USP monograph is currently referenced as a harmonised public standard. Published data for this specific configuration is limited, so analytical methods for assay and related substances should be qualified according to ICH Q2(R2).

Which Release Specifications Separate Oral and Injectable Butylphthalide API?

Table 1 presents representative route-specific release criteria. Individual marketing-authorisation dossiers may set tighter limits for specified impurities, especially enantiomeric impurity, based on toxicological qualification under ICH Q3A and ICH M7.

Injectable grade bacterial endotoxin limits are often derived from the finished infusion volume rather than the bulk API alone; a common calculation is NMT 0.5 EU/mg when the maximum adult daily dose is 100 mg, but the final limit should be calculated as K/M using Ph. Eur. 2.6.14 or USP <85>. Sterility and particulate matter tests are performed on the finished product because the bulk oily liquid cannot be tested as a final aqueous injection. The oral grade may permit a higher bioburden, but a specification is still set for mesophilic bacteria and fungi to prevent excessive microbial load in nonsterile granulation and capsule filling. Microbiological quality for nonsterile oral grade should comply with Ph. Eur. 5.1.4 or USP <1111>.

For liquid-filled hard capsule and softgel production, butylphthalide is diluted in a lipid carrier system selected for compatibility and oxidative stability. Medium-chain triglycerides and soybean oil are common carriers; oleoyl macrogolglycerides may be added to adjust dispersibility in aqueous media. The fill mass is deaerated under vacuum at –0.08 MPa for 30–60 minutes to remove dissolved air before encapsulation. Rotary-die softgel encapsulation requires fill viscosity below 1000 mPa·s at 25°C to maintain ribbon sealing; if viscosity exceeds 1500 mPa·s, processing defects such as leakers and inconsistent shell thickness may occur. High-shear dispersion of the API in the lipid phase at 3000–5000 rpm for 15–30 minutes is used for initial mixing. Softgel shells are dried in tumble dryers to shell moisture 7–9% w/w, and fill-content uniformity is verified by extraction and HPLC against a qualified method.

Direct compression is not feasible for granule-based oral forms because the API is liquid. The primary processing route is adsorption onto high-surface-area excipients such as fumed silica, calcium silicate, or silicified microcrystalline cellulose. The adsorbent is charged to a high-shear granulator, and butylphthalide is metered by peristaltic pump over 10–20 minutes while the main impeller operates at low speed 200–400 rpm. If the addition rate exceeds the adsorption rate, free oil coats the granulator wall and causes batch-to-batch potency drift. After adsorption, the premix is blended with filler, disintegrant, and lubricant in a bin blender at 10–25 rpm for 15 minutes. Granules may be filled into sachets or coated with a polymer film to mask the oily taste; coating uniformity is checked by disintegration testing per Ph. Eur. 2.9.1 or USP <701>.

Particle size distribution for sachet granules is controlled by sieve analysis according to Ph. Eur. 2.9.12. The target size range is 0.2–0.8 mm; material below 0.15 mm may generate dust and compromise content uniformity, while material above 1.0 mm can segregate during filling. Fluid-bed drying of wet granulate is performed at inlet air temperature 40–60°C and product temperature 25–35°C to avoid evaporating the API or causing oxidative degradation. Residual moisture after drying is controlled to ≤2.0% w/w for granule-based oral forms. For coated granules, a polymer film of hydroxypropyl methylcellulose or ethylcellulose is applied in a Wurster column at spray rate 5–15 g/min/kg; coating weight gain is monitored and endpoint is determined by drug-release testing per USP <711> rather than visual appearance alone.

When the Oily API Is Adsorbed onto Silicified Microcrystalline Cellulose for Tablet Compression

The unit operation is limited by the maximum liquid adsorption capacity of the adsorbent. Fumed silica and calcium silicate typically accept 0.2–0.4 g/g of oily liquid before the blend becomes cohesive; for butylphthalide, the actual maximum is determined by incremental addition under high-shear mixing at 25°C because published data for this specific configuration is limited. In a 600 L high-shear granulator with chopper speed 1500–3000 rpm, the API is sprayed or pumped onto the pre-mixed adsorbent and microcrystalline cellulose bed. Mixing continues until visual absence of free oil and a contact-angle or drop-point test confirms complete adsorption. The premix is then blended with disintegrant and lubricant. Rotary tablet compression at 40–80 rpm and compression force 8–15 kN can produce tablets with friability below 1.0% when tested according to Ph. Eur. 2.9.7. Hardness is formulation-dependent; a starting target of 50–100 N is used, but commercially acceptable hardness must be linked to disintegration and dissolution performance rather than set as a universal specification. Tablets containing adsorbed liquid API may show reduced tensile strength at high drug loading because the liquid phase disrupts particle bonding; formulators should not exceed the critical adsorption threshold without adding additional dry binder.

If complete adsorption is not achieved, tablet surfaces exhibit mottling and hardness variability, and die-wall friction increases during compression. The defect is detected by extraction assay on tablet cores sampled at the beginning, middle, and end of the compression run; relative standard deviation above 5.0% indicates non-uniform liquid distribution. In such cases, the granulate should be reworked by adding adsorbent and remixing rather than increasing compression force, because excessive force may expel oil and accelerate picking or sticking.

Injectable manufacture of butylphthalide requires a different stabilisation strategy because the API has negligible aqueous solubility. Published aqueous solubility data for butylphthalide is limited; the API is practically insoluble in water and therefore requires a lipid carrier, cyclodextrin-based solubilisation, or an oil-in-water emulsion. An oil-in-water emulsion approach is used when the API is dissolved in a biocompatible oil phase and homogenised with an aqueous phase containing purified egg lecithin and an isotonicity agent such as glycerol. The coarse emulsion is prepared in a high-shear rotor-stator mixer at 10,000–20,000 rpm, then passed through a high-pressure homogeniser at 800–1200 bar for 5–7 passes. The resulting mean globule diameter is maintained below 500 nm and the large-diameter tail below 0.05% for globules greater than 5 µm, as measured by laser diffraction and consistent with USP <729>. Terminal steam sterilisation at 121°C for 15 minutes may be applied if the emulsion withstands the thermal cycle without phase separation or free oil formation; otherwise, aseptic processing with pre-sterilised components is used. The filled product should be placed in Type I glass bottles or non-PVC infusion bags with an oxygen-barrier overwrap. PVC containers are discouraged because the lipophilic API may partition into the plasticiser; extraction studies under ICH Q1A conditions should be performed before any primary packaging change.

Filtration of the bulk oil phase through 0.2 µm sterilising-grade membranes is not always possible because the oil phase may increase viscosity; therefore, sterilisation validation should include the full emulsion rather than the API alone. The emulsion should be checked for zeta potential and globule size distribution before and after terminal sterilisation to confirm physical stability. A zeta potential more negative than –30 mV is generally associated with electrostatic stabilisation, but the acceptance value must be established for the specific lecithin and pH. Published data for this specific configuration is limited; therefore, pilot-scale stability data under ICH Q1A and Q1B should support the chosen formulation and primary packaging.

Comparative Pharmacology in Ischaemic Stroke Management

Butylphthalide differs from other small-molecule stroke therapies in administration flexibility and mechanism breadth. Edaravone is primarily supplied as an injectable free-radical scavenger and lacks a common oral solid stroke formulation. Citicoline is available in oral and injectable forms but acts as a phospholipid precursor and has produced inconsistent outcomes in large randomised stroke trials. Ginkgolide B is a platelet-activating factor antagonist with a narrower single-receptor target profile. These distinctions are product-design differences, not evidence of superior clinical efficacy; direct head-to-head outcome data for butylphthalide against these comparators are not available in publicly accessible registration dossiers. A classification summary is provided in Table 2.

Regulatory status also differs. Butylphthalide is registered primarily in the People’s Republic of China through the National Medical Products Administration for ischaemic stroke; edaravone has registration for amyotrophic lateral sclerosis in some jurisdictions and for acute ischaemic stroke in others. Citicoline is marketed in multiple jurisdictions but has not demonstrated consistent efficacy in large placebo-controlled stroke trials. Ginkgolide B formulations are used mainly in China and parts of Europe as supportive therapy. These regulatory differences affect dossier requirements, pharmacovigilance obligations, and local product labelling, but they do not establish therapeutic equivalence or superiority. Formulators preparing comparator studies should refer to the current approved label in the target jurisdiction rather than relying on mechanism class alone.

Incoming quality control of butylphthalide API should include identity confirmation by IR and HPLC retention time, assay, related substances, residual solvents, heavy metals, and, for injectable grade, bacterial endotoxin and subvisible particulate matter. Because the API is an oily liquid, sampling must ensure homogeneity; the container should be warmed to 25–30°C and mixed before sampling if storage has caused viscosity increase. Storage is recommended in sealed, light-resistant containers under nitrogen at 15–25°C; the retest period should be based on manufacturer stability data under ICH Q1A or ICH Q1B photostability conditions. The product should not be exposed to strong oxidising agents, strong alkali, or unlined carbon steel. Transfer operations should use closed piping or local exhaust ventilation to control oily aerosol exposure. For dossier development, the active substance master file should include route-specific specification addenda and process validation data covering the intended oral or injectable finished dosage form. No additional unproven therapeutic claims should be inferred from the dual-route presentation.